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ABSTRACT 
 
Long-term clinical outcomes of new-generation drug-eluting stents in complex anatomic and clinical 
settings are not well defined. This study assessed the impact of patient and lesion complexity on 2-year 
outcomes following coronary revascularization with ultrathin strut biodegradable-polymer (BP) 
sirolimus-eluting stents (SES) vs. durable-polymer (DP) everolimus-eluting stents (EES). In a 
pre-specified analysis of the BIOSCIENCE randomized trial (NCT01443104), complex patients (911 of 
2,119; 43%) were defined by the presence of acute ST-elevation myocardial infarction; left ventricular 
ejection fraction ≤30%; renal dysfunction; insulin-treated diabetes; treatment of ostial lesion, bypass graft, 
unprotected left main lesion; or 3-vessel intervention. The primary endpoint was target-lesion failure 
(TLF), a composite of cardiac death, target-vessel myocardial infarction (MI), and clinically-indicated 
target lesion revascularization. At 2 years, complex compared with simple patients had a higher risk of 
TLF (14.5% vs. 7.4%, RR 2.05, 95% CI 1.56-2.69; p<0.001). The difference was sustained beyond 1 year 
on landmark analysis. Complex patients had higher rates of the patient-oriented composite endpoint 
(POCE) of death, any MI, or any revascularization (23% vs. 14.4%; p<0.001) as well as definite stent 
thrombosis (1.6% vs. 0.4%, p=0.006). There were no differences in TLF and POCE between the BP-SES 
vs. DP-EES, consistently among simple and complex patients. In conclusion, patient and lesion 
complexity had a durable adverse impact on clinical outcomes throughout 2 years of follow-up in this 
all-comers randomized trial. Safety and efficacy of new-generation BP-SES and DP-EES were 
comparable, irrespective of complexity status.    
 
Keywords: biodegradable polymer; drug-eluting stent; complex intervention.   
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New-generation drug-eluting stents (DES) are frequently implanted in complex anatomic and 
clinical settings1,2 and are recommended for unrestricted use across patient and lesion subsets.3,4 Studies 
analyzing bare-metal stents (BMS) and early-generation DES showed less favorable outcomes in patients 
treated for complex (“off-label”) indications.4-6 In contrast, few data exist regarding new-generation DES 
in complex patients and lesions, and are limited by short- to mid-term follow-up durations.7,8 
Biodegradable polymer DES (BP-DES) were conceived to overcome safety issues of early-generation 
durable polymer (DP) DES, as polymer remnants within the arterial wall may be implicated in late stent 
thrombosis or delayed restenosis. The BIOSCIENCE randomized trial reported non-inferiority of the 
ultra-thin strut BP sirolimus-eluting stent (BP-SES) compared with DP everolimus-eluting stent 
(DP-EES).9 Other studies showed clinical10,11 and angiographic non-inferiority12 of thin-strut BP platforms. 
Whether these performance profiles are maintained in patients undergoing complex interventions remains 
unknown. This study sought to determine the impact of patient and lesion complexity on 2-year clinical 
outcomes following revascularization with new-generation DES, and to compare the safety and efficacy of 
ultrathin-strut BP-SES vs. DP-EES in relation to complexity status in a large-scale randomized trial with 
minimal exclusion criteria.  
 
Methods 
This is a pre-specified analysis of the BIOSCIENCE trial (NCT01443104),9,13 a prospective, 
multicenter trial that compared an ultrathin strut stent covered with a BP releasing sirolimus (Orsiro; 
Biotronik AG, Bülach, Switzerland) with a thin strut DP-EES (XIENCE PRIME/Xpedition®; Abbott 
Vascular, Santa Clara, CA, USA).13 Briefly, patients with stable coronary artery disease (CAD) or acute 
coronary syndrome (ACS) and at least 1 lesion with diameter stenosis >50% (de novo or restenosis) in a 
native vessel or bypass graft with reference vessel diameter between 2.25 and 4.0 mm were eligible for 
inclusion. There were no restrictions to the number of treated lesions or vessels. The study was approved 
by institutional ethics committees of all participating sites. All patients provided written informed consent.  
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Procedures were performed according to current standards.3 Procedural anticoagulation included 
unfractionated heparin 5,000 IU or 70-100 IU/kg. The use of glycoprotein IIb/IIIa inhibitors and 
bivalirudin was left at the operator’s discretion. Antiplatelet treatment was initiated before or at the time of 
PCI, and consisted of acetylsalicylic acid (ASA) in combination with a loading dose of clopidogrel 600mg, 
prasugrel 60mg, or ticagrelor 180mg. Dual antiplatelet therapy was recommended for 12 months and 
consisted of ASA 100 mg and a P2Y12 inhibitor, followed by ASA monotherapy indefinitely.   
We applied an extended definition of complexity including clinical, lesion-related, and procedural 
characteristics previously shown to predict adverse outcomes following PCI with new-generation DES.14 
Complex patients were defined by the presence of at least 1 of the following: acute STEMI (within 
24hours); left ventricular ejection fraction ≤30%; renal dysfunction (GFR<60ml/min); insulin-treated 
diabetes; and treatment of ostial lesion, bypass graft, unprotected left main lesion, or >2 vessels.   
An independent clinical events committee adjudicated all events. Myocardial infarction (MI) was 
defined according to an extended historical definition.15 Clinical follow-up was performed at 30 days, 12 
and 24 months. The pre-specified primary endpoint9,13 was target lesion failure (TLF), a composite of 
cardiac death, target-vessel MI, and clinically indicated target-lesion revascularization (TLR) at 2 years. 
Secondary endpoints included a patient-oriented composite endpoint (POCE) of all-cause death, any MI, 
or any revascularization; and individual components of composite endpoints. The principle safety 
endpoint was stent thrombosis, defined according to the Academic Research Consortium.16   
Continuous variables are summarized as mean ± standard deviation, and categorical ones as actual 
numbers and percentages. Baseline and procedural characteristics were compared using unpaired t-tests, 
chi square tests, or Fisher’s exact tests. P-values for lesion-level characteristics were based on general or 
generalized linear mixed models to account for the non-independence of lesions in the same patient. We 
used time to first event for each outcome and report Kaplan–Meier estimates of event rates. We used the 
Mantel–Cox method to calculate risk ratios (RR) with 95% confidence intervals (CI) from the log-rank 
test. Landmark Mantel-Cox’s models compared outcomes between complex and simple patients at 1 year, 
and the p-value for the interaction was based on the approximate chi square test for unequal rate ratios 
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(effect modification). For each event, patients were censored at the time of first event. Simple and 
complex patients treated with BP-SES were compared with those treated with DP-EES, and interaction p 
values were calculated. Analyses were performed according to the intention-to-treat principle with Stata 
version 14. A 2-sided p-value <0.05 was considered statistically significant.  
 
Results 
Out of 2,119 patients enrolled, 911 complex patients (43%) were allocated to BP-SES (n=487) or 
DP-EES (n=424). Simple patients (1,208; 57%) were randomized to BP-SES (n=576) or DP-EES (n=632) 
(Supplementary Figure 1). The most frequent complexity characteristics were acute STEMI (34.9%), 
renal dysfunction (32.7%), and insulin-treated diabetes (17.6%) (Figure 1). Compared with simple 
patients, complex patients were older, more commonly female, with more frequent history of previous 
revascularization (Table 1). Variables were well-balanced between the BP-SES and DP-EES arms for 
both complex and simple patients (Supplementary Table 1). Complex patients had a higher number of 
lesions treated, and received more stents per lesion with greater length and diameter (Table 2).  
The primary endpoint, TLF at 2 years, occurred in 128 complex patients (14.5%) vs. 86 simple 
patients (7.4%) (RR 2.05, 95% CI 1.56-2.69; p=0.001). Consistent differences were observed in all 
components of the primary endpoint (Table 3). Complex compared with simple patients had higher risk of 
the POCE (RR 1.67, 95% CI 1.36-2.05; p<0.001) and all-cause mortality (RR 2.81, 95% CI 1.87-4.24; 
p<0.001). Kaplan-Meier curves for TLF and POCE are shown in Figure 2. The risk of TLF and POCE 
was highest in patients with more than 1 complexity characteristics (Supplementary Figure 2). Definite 
stent thrombosis within 2 years was more frequent among complex patients (1.6% vs. 0.4%, p=0.006).  
Landmark analyses for TLF and POCE set at 30 days and 1 year are illustrated in Supplementary 
Figure 3 and Figure 3, respectively. Complex compared with simple patients had higher risk of TLF 
consistently up to 1 year (RR 1.77, 95% CI 1.27-2.46) and for the timeframe between 1 and 2 years (RR 
2.78, 95% CI 1.70-4.54) (pinteraction = 0.13). Similarly, the risk of POCE was higher in complex patients 
consistently during the first as well as the second year of follow-up (Figure 3 and Supplementary Table 
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2). Complex vs. simple patients had higher one-year rates of definite stent thrombosis (1.2% vs. 0.2%, 
p=0.002) but had similar rates of very late stent thrombosis (0.4% vs. 0.3%; p=0.69).  
Among complex patients, BP-SES and DP-EES were associated with similar risk of TLF (RR 0.76, 
95% CI 0.54-1.08; p=0.12), POCE (RR 0.99, 95% CI 0.76-1.31; p=0.97) (Figure 4), and definite stent 
thrombosis (RR 1.57, 95% CI 0.52-4.68; p=0.42) (Table 4). Similarly, no significant difference was 
observed between BP-SES and DP-EES with regard to TLF (RR 1.35, 95% CI 0.88-2.06; p=0.17), POCE 
(RR 1.22, 95% CI 0.90-1.66; p=0.19) and stent thrombosis throughout 2 years (RR 0.75, 95% CI 
0.12-4.52; p=0.75) among simple patients (Table 4). The DP-EES was associated with lower cardiac 
mortality among simple patients, but with higher cardiac mortality among complex patients (Table 4).  
 
Discussion 
The findings of the present study can be summarized as follows. First, patient and lesion complexity 
was associated with higher long-term risk of stent-related and patient-related adverse events following PCI 
with new-generation DES. Second, complexity had a durable adverse impact extending beyond the first 
year of follow-up. Third, primary safety and efficacy endpoints were comparable between the ultra-thin 
strut BP-SES and DP-EES, consistently among complex and simple patients. These findings add to 
previous investigations that assessed complex interventions using earlier-generation devices.5,6 They also 
build upon studies that demonstrated comparable efficacy and safety profiles of thin-strut BP-DES vs. 
DP-EES but did not address the possibly interrelating effect of patient and lesion complexity.9-12  
 
While on-label FDA indication for coronary DES is limited to low-risk, stable CAD patients with 
single simple lesions, PCI is frequently performed in more complex settings. Observational studies with 
primarily early-generation DES showed marked attenuation of the benefits of DES with off-label vs. 
on-label use.4,5 New-generation DES have improved the safety and efficacy of PCI3,4; however, there are 
limited data regarding long-term performance of new-generation DES in complex settings.7 The present 
analysis from a broadly inclusive contemporary trial uniquely addressed the impact of patient and lesion 
complexity on long-term clinical outcomes with the unrestricted use of 2 new-generation DES. 
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Interventions in complex patients were associated with less-favorable outcomes including 2-fold higher 
risk of TLF, 3-fold higher mortality, and increased risk of all ischemic endpoints, particularly among 
patients with multiple concomitant complexity features. These differences emerged following the early 
phase (30 days), they extended beyond the first year and were at least as pronounced during the second 
year of follow-up. These observations may have implications for long-term risk stratification and patient 
management, as complex patients are likely to benefit more from aggressive, sustained secondary 
prevention therapies.17   
Defining characteristics of complexity in this study included comorbidities with a well-established 
role in the pathobiology of atherosclerotic disease and in-stent restenosis (insulin-treated diabetes, renal 
dysfunction); clinical conditions portending sustained atherothrombotic risk (acute STEMI); and 
challenging anatomic settings known to adversely affect procedural and longer-term PCI outcomes. These 
complexity features have been closely linked to adverse PCI outcomes in previous relevant reports 
focusing on earlier devices.5,8   
The rates of definite stent thrombosis within 2 years (0.9%) is comparable with other studies with 
new-generation DES,18 but was 4-fold increased among complex vs. simple patients. Whether complex 
patients might benefit from more prolonged dual antiplatelet therapy or potent P2Y12 inhibitors even in 
non-ACS settings merits investigation in dedicated studies, also accounting for individual bleeding risk. 
These findings require cautious interpretation owing to the small numbers of events, and the possibly 
heterogeneous ischemic risk among patients encompassed in our complexity definition.  
Decision-making regarding the preferred modality of coronary revascularization (PCI vs. CABG) is 
a challenging process accounting for patient-related factors, anatomic configurations, and procedural 
feasibility.3 The present findings should be interpreted in view of the following considerations. First, PCI 
is the cornerstone for management of acute STEMI (the most common complexity feature in this study), 
whereas CABG has very limited role in this context.3 Second, improvements in stent technologies appear 
to have narrowed the outcome gap between CABG and PCI in patients with advanced, complex disease.19 
Third, several of the complexity characteristics are also known to adversely affect prognosis following 
Published in final edited form as: Am J Cardiol. 2017 Feb 15;119(4):501-507. 
doi: 10.1016/j.amjcard.2016.10.038 
 
- 8 -   
 
 
 
bypass surgery, including insulin-treated diabetes,20 depressed left ventricular function,21 and renal 
dysfunction.22 Therefore, rather than challenging the value of new-generation DES in complex scenarios, 
the present observations point to the importance of preventing long-term PCI complications particularly 
among complex patients. Potential means may include meticulous attention to the acute PCI result, 
possibly intracoronary imaging-guided interventions in selected anatomic subsets,3,23 and optimization of 
post-PCI antithrombotic treatment and secondary prevention therapies.9   
New-generation DES have improved late and very-late safety compared with early-generation DES. 
The combination of an ultrathin stent platform with a BP represents the next generation of coronary stent 
technology. While thin-strut BP-DES have demonstrated equivalent clinical and angiographic outcomes 
compared with the DP-EES,9-12 this is the first report assessing the relative safety and efficacy of a 
new-generation BP-DES specifically in complex patient and lesion subsets. We found that the BP-SES 
matched the clinical performance of DP-EES, the contemporary benchmark for PCI. Pre-specified primary 
endpoints (TLF, POCE) did not differ in relation to stent type, irrespective of complexity status. The 
hypothesis-generating observation of lower cardiac mortality of BP-SES vs. DP-SES treated patients in 
the complex, but not in the simple patient group requires further investigation. Great caution is required in 
interpreting these results in view of the modestly sized subgroups after stratification for both complexity 
status and stent type.      
This study has limitations. First, our findings are presented as hypothesis-generating only, being a 
post hoc analysis of a trial not designed to assess outcomes in relation to complexity. Second, the study 
was powered for the primary endpoint but is underpowered to detect differences in individual components 
or rare events, such as stent thrombosis. Third, this analysis was not designed to address the causal vs. 
associative interrelation of complexity factors with adverse outcomes. Fourth, although the definition of 
complexity was not pre-defined, the present complexity analysis was pre-specified in the study protocol.13 
Finally, the biodegradable polymer of the BP-SES degrades over a period of 12 to 24 months; hence, 
potential differences in outcomes may only emerge during very long-term (more than 2-year) follow-up.    
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Figures  
 
Figure 1. Frequency of complexity characteristics (A) and number of complexity features per patient (B) 
among complex patients (n=911).  
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Figure 2. Kaplan-Meier curves for the primary endpoint (A) and the patient-oriented composite endpoint 
(POCE) (B) within 2-year follow-up in complex and simple patients.   
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Figure 3. Kaplan-Meier curves for the primary endpoint (A) and the patient-oriented composite endpoint 
(POCE) (B) in relation to complexity status with landmark set at one year.  
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Figure 4. Kaplan-Meier curves for the primary endpoint (A, B) and the patient-oriented composite 
endpoint (POCE) (C, D) in relation to stent type among complex patients (left) and simple patients (right).  
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Tables 
 
Table 1  
Baseline clinical characteristics   
 Variable  
Complex patients 
(n=911) 
Simple patients 
(n=1,208) 
P value 
Age (years) 67.3±12.3 65.1±10.7 <0.001 
Men 678 (74.4%) 956 (79.1%) 0.01 
Body mass index (kg/m2) 27.8±4.6 27.5±4.4 0.18 
Diabetes mellitus  300 (32.9%) 186 (15.4%) <0.001 
   Insulin-treated  160 (17.6%) 0  <0.001 
Hypertension  628/909 (69.1%) 806 (66.7%) 0.26 
Hypercholesterolemia  603 (66.2%) 825 (68.4%) 0.30 
Current smoker  244/910 (26.8%) 365 (30.3%) 0.09 
Family history of CAD  241/907 (26.6%) 346 (28.7%) 0.28 
Previous PCI  308 (33.8%) 309 (25.6%) <0.001 
Previous coronary bypass    125 (13.7%) 86 (7.1%) <0.001 
Atrial fibrillation  77 (8.5%) 86 (7.1%) 0.28 
Peripheral vascular disease  95 (10.4%) 81 (6.7%) 0.00 
Renal dysfunction (GFR<60 ml/min)  281 (32.7%) 0 <0.001 
Clinical presentation   <0.001 
Unstable angina pectoris   48 (5.3%) 104 (8.6%)  
NSTEMI  172 (18.9%) 400 (33.1%)  
STEMI  339 (37.2%) 68 (5.6%)  
        Acute STEMI within 24h  318 (34.9%) 0   
Stable angina / silent ischemia  352 (38.6%) 635 (52.6%)  
Left ventricular ejection fraction ≤30% 82 (11.2%) 0 <0.001 
 
BP-SES = biodegradable polymer sirolimus-eluting stent; CAD = coronary artery disease; DP-EES = 
durable polymer everolimus-eluting stent; PCI = percutaneous coronary intervention.  
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Table 2  
Baseline lesion and procedural characteristics  
 Variable  
Complex patients 
(n = 911) 
Simple patients 
(n = 1,208)  
P value 
Number of lesions  1,422 1,717  
Target-vessel location per lesion    
Left main artery  46 (3.2%) 10 (0.6%) <0.001 
Left anterior descending artery  529 (37.2%) 799 (46.5%) <0.001 
Left circumflex artery  301 (21.2%) 410 (23.9%) 0.06 
Right coronary artery  459 (32.3%) 498 (29%) 0.03 
Bypass graft 87 (6.4%)  0   
Number of treated lesions per patient     0.009 
1 560 (61.5%) 811 (67.1%)  
2 233 (25.6%) 300 (24.8%)  
3 87 (9.5%) 83 (6.9%)  
4 or more   31 (3.4%) 14 (1.2%)  
Type of intervention per lesion*   0.49 
Stenting 1,355 (95.3%) 1,645 (95.8%)  
Ballooning 62 (4.4%) 67 (3.9%)  
Bypass grafting  1 (0.1%) 2 (0.1%)  
Failed PCI 4 (0.3%) 3 (0.2%)  
Restenotic lesion   180/1,421 (12.7%) 0 (0.0%)  
Total occlusion    330/1,418 (23.3%) 201 (11.7%) <0.001 
Thrombus aspiration    199/1,420 (14.0%) 72  (4.2%) <0.001 
Number of stents   1.33±0.66 1.32±0.60 0.79 
Total stent length (mm) 27.46±17.76 26.03±14.59 0.014 
Maximum stent diameter per lesion (mm) 3.07±0.50 3.01±0.48 0.001 
Overlapping stents   299 (22.1%) 367 (22.3%) 0.93 
   Long lesion (>20 mm)  56 (55.8%) 909 (55.3%) 0.74 
   Small-vessel per lesion (<2.75 mm)   555 (41%) 737 (44.8%) 0.03 
   Bifurcation treatment    222 (15.7%) 300 (17.6%) 0.16 
Type of stent per lesion    0.047 
   BP-SES 739 (54.5%) 771 (46.9%)  
 DP-EES 616 (45.5%) 871 (52.9%)  
   Other drug-eluting stent 0 2 (0.1%)  
   Bare-metal stent 0  5 (0.3%)  
 
*P-value for stenting vs. non-stenting per patient. 
 
Abbreviations as in Table 1. 
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Table 3  
Clinical outcomes at 2 years    
 
 Variable  
Complex patients  
(n = 911) 
Simple patients 
(n = 1208) 
Risk Ratio  
(95% CI) 
P value 
All-cause death 70 (7.8%) 34 (2.9%) 2.81 (1.87-4.24) <0.001 
   Cardiac death 47 (5.3%) 19 (1.6%) 3.38 (1.98-5.76) <0.001 
Myocardial infarction (any) 71 (8.3%) 64 (5.4%) 1.51 (1.08-2.11) 0.016 
Target-vessel myocardial infarction 52 (6.0%) 36 (3%) 1.96 (1.28-2.99) 0.002 
Repeat revascularization (any) 126 (14.8%) 113 (9.8%) 1.55 (1.21-2.00) 0.001 
Clinically-indicated TLR 66 (7.8%) 44 (3.9%) 2.08 (1.42-3.04) <0.001 
Clinically-indicated TVR 85 (10.0%) 60 (5.3%) 1.97 (1.42-2.74) <0.001 
Target lesion failure* 128 (14.5%) 86 (7.4%) 2.05 (1.56-2.69) <0.001 
Target vessel failure** 146 (16.6%) 105 (9%) 1.92 (1.49-2.47) <0.001 
Patient-oriented composite endpoint*** 204 (23%) 169 (14.4%) 1.67 (1.36-2.05) <0.001 
BARC ≥3 bleeding 41 (4.7%) 31 (2.6%) 1.81 (1.13-2.88) 0.01 
Stent thrombosis      
   Definite  14 (1.6%) 5 (0.4%) 3.82 (1.37-10.63) 0.006 
   Probable  43 (4.9%) 31 (2.6%) 1.87 (1.18-2.97) 0.007 
   Definite or probable  56 (6.4%) 34 (2.9%) 2.23 (1.46-3.42) <0.001 
 
BARC = Bleeding Academic Research Consortium; TLR = target-lesion revascularization; TVR = 
target-vessel revascularization.    
   
* Composite of cardiac death, target-vessel MI, and clinically indicated TLR.  
** Composite of cardiac death, any MI, and TVR.    
*** Composite of death, MI, or any repeat revascularization. 
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Table 4  
Clinical outcomes at 2 years in complex and simple patients stratified by allocated stent type   
 
  Complex patients Simple patients 
  BP-SES 
(n = 487) 
DP-EES 
(n = 424) 
Risk Ratio  
(95% CI) 
P value BP-SES 
(n = 576) 
DP-EES 
(n = 632) 
Risk Ratio  
(95% CI) 
P value 
All-cause death 39 (8.2%) 31 (7.4%) 1.09 (0.68-1.75) 0.71 23 (4.1%) 11 (1.8%) 2.35 (1.14-4.82) 0.017 
  Cardiac death 18 (3.9%) 29 (7%) 0.54 (0.30-0.97) 0.036 15 (2.7%) 4 (0.7%) 4.22 (1.40-12.73) 0.005 
Myocardial infarction (any) 35 (7.6%) 36 (9.1%) 0.84 (0.53-1.34) 0.46 27 (4.8%) 37 (5.9%) 0.81 (0.49-1.33) 0.41 
Target-vessel MI 27 (5.8%) 25 (6.2%) 0.94 (0.54-1.62) 0.81 15 (2.6%) 21 (3.4%) 0.79 (0.41-1.54) 0.49 
Cardiac death or MI 50 (10.7%) 61 (14.8%) 0.71 (0.49-1.03) 0.07 42 (7.5%) 40 (6.4%) 1.17 (0.76-1.80) 0.48 
Repeat revascularization (any) 69 (15.1%) 57 (14.5%) 1.06 (0.75-1.51) 0.74 57 (10.5%) 56 (9.1%) 1.16 (0.80-1.68) 0.43 
Clinically-indicated TLR 37 (8.1%) 29 (7.5%) 1.12 (0.69-1.82) 0.65 22 (4.2%) 22 (3.6%) 1.13 (0.62-2.04) 0.69 
Clinically-indicated TVR 48 (10.5%) 37 (9.5%) 1.14 (0.74-1.75) 0.55 29 (5.5%) 31 (5.1%) 1.06 (0.64-1.75) 0.83 
Target lesion failure 60 (12.8%) 68 (16.5%) 0.76 (0.54-1.08) 0.12 47 (8.6%) 39 (6.3%) 1.35 (0.88-2.06) 0.17 
Target vessel failure 69 (14.7%) 77 (18.7%) 0.78 (0.56-1.07) 0.12 55 (10%) 50 (8.1%) 1.23 (0.84-1.81) 0.29 
POCE 109 (23%) 95 (23%) 0.99 (0.76-1.31) 0.97 88 (15.8%) 81 (13%) 1.22 (0.90-1.66) 0.19 
Stent thrombosis          
  Definite  9 (1.9%) 5 (1.2%) 1.57 (0.52-4.68) 0.42 2 (0.4%) 3 (0.5%) 0.75 (0.12-4.52) 0.75 
  Probable  18 (3.9%) 25 (6.1%) 0.62 (0.34-1.14) 0.12 12 (2.1%) 19 (3%) 0.70 (0.34-1.44) 0.32 
  Definite or probable  26 (5.6%) 30 (7.3%) 0.75 (0.44-1.27) 0.28 14 (2.5%) 20 (3.2%) 0.77 (0.39-1.54) 0.46 
BARC ≥3 bleeding 21 (4.4%) 20 (4.9%) 0.91 (0.49-1.68) 0.76 15 (2.7%) 16 (2.6%) 1.04 (0.52-2.11) 0.90 
 
Abbreviations as in Table 3.   
 
